A role for melanocortin agonists in treating male and female sexual dysfunction

doi:10.1016/J.DDSTR.2006.11.011

Paper

A role for melanocortin agonists in treating male and female sexual dysfunction

Published Dec 1, 2006 · A. Shadiack, SHUBH D. Sharma, D. Earle

Drug Discovery Today: Therapeutic Strategies

UNKNOWN SJR score

0

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Melanocortin receptor agonists, such as bremelanotide, improve male and female sexual function by acting on central nervous system receptors.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

A role for melanocortin agonists in treating male and female sexual dysfunction

Sign up to use Study Snapshot

References

Topical Alprostadil Treatment of Female Sexual Arousal Disorder

Topical alprostadil shows potential in improving sexual arousal and successful encounters in female sexual arousal disorder patients, but its effectiveness remains inconsistent and not reproducible in all trials.

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

Bremelanotide shows potential in positively affecting sexual desire and arousal in premenopausal women with female sexual arousal disorder, warranting further evaluation in at-home studies.

Sexual Desire and Arousal Disorders in Women

This patient should be assessed for sexual desire and arousal disorders, and treated with lubrication and cognitive behavioral therapy to improve sexual thoughts, fantasies, and orgasms.

The management of phosphodiesterase-5 (PDE5) inhibitor failure.

PDE5 inhibitor failure can be managed through alternative treatments, combination therapies, and early treatment of vascular risk factors.

Women's sexual dysfunction: revised and expanded definitions

The revised definitions of women's sexual disorders consider multiple reasons for initiating sexual activity and emphasize the importance of subjective sexual arousal, potentially improving assessment and management of dysfunction.

Citations